Liquid Biopsy: Page 3

Natera supports guideline proposing donor-derived cfDNA testing for heart transplant surveillance

By LabPulse.com staff writers

The International Society for Heart and Lung Transplantation proposes monitoring for rejection with noninvasive biomarkers or biopsy monthly during the first six months post-transplant, as well as testing in the ninth and 12th months post-transplant.

December 23, 2022

Menarini study demonstrates impact of circulating tumor cell counting on metastatic breast cancer survival

By LabPulse.com staff writers

The data demonstrated that a single assessment of circulating tumor cell count by CellSearch before treatment commences may lead to increased overall survival in patients with metastatic breast cancer.

December 22, 2022

Foundation Medicine obtains FDA approval for NSCLC CDx

By LabPulse.com staff writers

The blood-based test’s first group approval improves physicians’ ability to identify patients in this population for treatment with certain FDA-approved tyrosine kinase inhibitors, Foundation Medicine said.

December 21, 2022

Biodesix nabs positive coverage decisions from four private payors

By LabPulse.com staff writers

The firm’s Nodify XL2 test will now be covered for enrollees of Blue Cross of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician’s Health Plan (CDPHP) of New York.

December 19, 2022

Agilent announces FDA approval for non-small cell lung cancer CDx

By LabPulse.com staff writers

Resolution ctDx First is a liquid biopsy next-generation sequencing (NGS) assay; it has also been approved by the FDA for tumor profiling of the epidermal growth factor receptor (EGFR) gene in patients with NSCLC.

December 13, 2022

Swedish firm Elypta developing multicancer early detection test using glycosaminoglycan biomarkers

By LabPulse.com staff writers

The firm this week announced the publication of research showcasing the multicancer early detection (MCED) potential of glycosaminoglycans as biomarkers of tumor metabolism.

December 7, 2022

Natera announces results for NIPT in twin-pregnancy clinical study

By LabPulse.com staff writers

Using single-nucleotide polymorphism technology, the test analyzes fetal DNA obtained through a blood draw from the mother.

December 7, 2022

Personalis to collaborate with UCSF on colorectal cancer treatment study

By LabPulse.com staff writers

The study will use the Next Personal assay to evaluate circulating tumor DNA (ctDNA)-based signatures associated with treatment response and adverse events in a cohort of patients with late-stage CRC who are receiving a combination therapy.

November 30, 2022

University of Tokyo researchers developing noninvasive method for early detection of childhood chronic kidney disease

By Jared Berberabe

By analyzing the variations in protein levels in collected urinary extracellular vesicles, the researchers believe they have discovered a first-step approach that could lead to earlier diagnosis of the disease in children.

November 9, 2022

Delfi Diagnostics to present proof-of-concept data for liver cancer detection platform

By LabPulse.com staff writers

Delfi Diagnostics will present data on the efficacy of their liver cancer detection platform at the American Association for the Study of Liver Disease annual meeting.

October 28, 2022

nRichDX launches products for researchers developing liquid biopsy assays

By LabPulse.com staff writers

Both products are used with nRichDX’s Revolution Sample Prep System. Researchers use the system for high-yield extraction of rare cfDNA from 1 mL to 20 mL of either plasma or urine samples.

October 24, 2022

Liquid biopsy diagnostics firm DiaCarta going public on NYSE through SPAC

By LabPulse.com staff writers

The equity valuation of DiaCarta under the proposed combination is $460 million. DiaCarta is a translational genomics and molecular diagnostics firm.

October 14, 2022

Previous Page

Page 3 of 4

Next Page